Recombinant Human Soluble Thrombomodulin in Patients with Sepsis-Associated Coagulopathy: Another Negative Sepsis Trial?

JAMA - Journal of the American Medical Association

Volumn 321, Issue 20, 2019, Pages 1978-1980

  Van Der Poll, Tom ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; BRADYKININ; EPIDERMAL GROWTH FACTOR; FIBRINOGEN; HIGH MOBILITY GROUP B1 PROTEIN; LECTIN; PROTEIN C; RECOMBINANT THROMBOMODULIN; THROMBOMODULIN;

ALL CAUSE MORTALITY; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BINDING SITE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL ADHESION; CELL PROTECTION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; IMMUNE RESPONSE; MORTALITY RATE; PATHOGENESIS; PLATELET COUNT; PRIORITY JOURNAL; PROTEIN BINDING; RESPIRATORY FAILURE; REVIEW; RISK REDUCTION; SAMPLE SIZE; SEPSIS; DISSEMINATED INTRAVASCULAR CLOTTING;

DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; SEPSIS; THROMBOMODULIN;

EID: 85065832271     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2019.5792     Document Type: Review

References (12)

1. Singer M, Deutschman CS, Seymour CW, The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315 (8): 801-810. doi: 10.1001/jama.2016.0287 26903338
2. Saito S, Uchino S, Hayakawa M,; Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study group. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J Crit Care. 2019; 50: 23-30. doi: 10.1016/j.jcrc.2018.11.009 30471557
3. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016; 2: 16037. doi: 10.1038/nrdp.2016.37 27250996
4. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017; 149: 38-44. doi: 10.1016/j.thromres.2016.11.007 27886531
5. Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2016; 14 (3): 518-530. doi: 10.1111/jth.13230 26670422
6. Vincent J-L, Francois B, Zabolotskikh I, Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial [published online May 19, 2019]. JAMA. doi: 10.1001/jama.2019.5358
7. Loghmani H, Conway EM. Exploring traditional and nontraditional roles for thrombomodulin. Blood. 2018; 132 (2): 148-158. doi: 10.1182/blood-2017-12-768994 29866818
8. Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol. 2013; 79 (3): 294-298. 23241735
9. Saito H, Maruyama I, Shimazaki S, Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007; 5 (1): 31-41. doi: 10.1111/j.1538-7836.2006.02267.x 17059423
10. Vincent JL, Ramesh MK, Ernest D, A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013; 41 (9): 2069-2079. doi: 10.1097/CCM.0b013e31828e9b03 23979365
11. De Cristofaro R, De Candia E, Landolfi R. Effect of high-and low-molecular-weight heparins on thrombin-thrombomodulin interaction and protein C activation. Circulation. 1998; 98 (13): 1297-1301. doi: 10.1161/01.CIR.98.13.1297 9751678
12. Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. Thromb Haemost. 2019; 119 (1): 56-65. doi: 10.1055/s-0038-1676345 30597500